International Journal of Pancreatology

, Volume 6, Issue 2, pp 109–118 | Cite as

Long-term effect of tumor necrosis factor and gamma interferon in human pancreatic carcinoma cells

  • Arthur B. Raitano
  • Philip Scuderi
  • Murray Korc


The long-term cytotoxic/cytostatic effects of recombinant human tumor necrosis factor alpha (rhTNF) and gamma interferon (rhIFN-7) were studied in five human pancreatic carcinoma cell lines. The pancreatic tumor cell lines were heterogenous in their response to individual cytokines. During a 7-d incubation, MIA PaCa-2 cells were more sensitive to rhTNF than rhIFN-γ, whereas ASPC-1, T3M4, and COLO 357 cells were more sensitive to rhIFN-γ than rhTNF. PANC-1 cells were relatively insensitive to both cytokines. In a previous report, we demonstrated synergistic cytotoxic effects of rhTNF and rhIFN-γ during 48-h incubations in ASPC-1 and COLO 357 cells (Raitano et al,Pancreas, April, 1990). In this study, a 7-d treatment with both rhTNF and rhIFN-γ did not produce synergistic effects in any of the cell lines. However, a 24-h treatment with rhIFN-γ, followed by removal of the cytokine, markedly increased the long-term cytotoxic/cytostatic effects of rhTNF in ASPC-1, COLO 357, and T3M4 cells. In contrast, a similar pretreatment with rhTNF did not increase the long-term cytotoxic/cytostatic effects of rhIFN-γ in any of the cell lines. These data suggest that, in some human pancreatic carcinoma cell lines, rhIFN-γ may be especially useful in the long-term suppression of growth. Furthermore, brief pulses of rhIFN-γ may also be especially efficacious when followed by a subsequent prolonged exposure of cells to rhTNF.

Key Words

Cytokines cytotoxicity HLA-DR tumor cells 



bovine serum albumin


fetal bovine serum


Hank’s balanced salt solution


gamma interferon


phosphate-buffered saline


recombinant human


tumor necrosis factor


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Cubilla AL, Fitzgerald PJ. Cancer of the exocrine pancreas: the pathological aspects. CA—A Cancer Journal for Clinicians 1985; 35: 2–35.PubMedCrossRefGoogle Scholar
  2. 2.
    Wang AM, Creasey AA, Ladner MB, Lin LS, Strickler J, Van Arsdell JN, Yamamoto R, Mark, DF. Molecular cloning of the complementary DNA for human tumor necrosis factor. Science (Washington, DC) 1985; 228: 149–154.CrossRefGoogle Scholar
  3. 3.
    Gray PW, Leung DW, Pennica D, Yelverton E, Najarian R, Simonsen CC, Derynck R, Sherwood PJ, Wallace DM, Berger SL, Levinson AD, Goeddel DV. Expression of human immune interferon cDNA in E. coli and monkey cells. Nature (London) 1982; 295: 503–508.CrossRefGoogle Scholar
  4. 4.
    Spriggs DR, Sherman ML, Frei E, Kufe DW. Clinical studies with tumour necrosis factor. Ciba Found. Symp. 1987; 131: 206–227.PubMedGoogle Scholar
  5. 5.
    Goldstein D, Laszlo J. The role of interferon in cancer therapy: a current perspective. CA—Cancer Journal for Clinicians 1988; 38: 258–277.CrossRefGoogle Scholar
  6. 6.
    Sugarman BJ, Aggarwal BB, Hass PE, Figari IS, Palladino MA, Shepard HM. Recombinant human tumor necrosis factor-α: effects on proliferation of normal and transformed cells in vitro. Science (Washington, DC) 1985; 230: 943–945.CrossRefGoogle Scholar
  7. 7.
    Fransen L, Van Der Heyden, J, Ruysschaert R, Fiers W. Recombinant tumor necrosis factor: its effect and its synergism with interferon-γ on a variety of normal and transformed human and mouse cell lines. Eur. J. Cancer Clin. Oncol. 1986; 22: 419–426.PubMedCrossRefGoogle Scholar
  8. 8.
    Raitano AB, Scuderi P, Korc M. Binding and biological effects of tumor necrosis factor and gamma interferon in human pancreatic carcinoma cells. Pancreas 1990; 5; in press.Google Scholar
  9. 9.
    Schmiegel WH, Caesar J, Kalthoff H, Greten H, Schreiber H W, Thiele H G. Antiprolif-erative effects exerted by recombinant tumor necrosis factor-α: (rTNF-α) and interferon- γ (rIFN-γ) on human pancreatic tumor cell lines. Pancreas 1988; 3: 180–188.PubMedCrossRefGoogle Scholar
  10. 10.
    Raitano AB, Scuderi P, Korc M. Gamma interferon up-regulates tumor necrosis factor receptors in COLO 357 human pancreatic carcinoma cells. Clinical Res. 1989; 37: 371A.Google Scholar
  11. 11.
    Rosa F, Fellous M. The effect of gamma-interferon on MHC antigens. ImmunoL Today 1984; 5: 261.CrossRefGoogle Scholar
  12. 12.
    Morgan RT, Woods LK, Moore GE, Quinn LA, McGavran L, Gordon SG. Human cell line (COLO 357) of metastatic pancreatic adenocarcinoma. Int. J. Cancer 1980 25: 591–598.PubMedCrossRefGoogle Scholar
  13. 13.
    Okabe T, Yamuguchi N, Ohsawa N. Establishment and characterization of a carcino-embryonic antigen (CEA)-producing cell line from a human carcinoma of the exocrine pancreas. Cancer 1983; 51: 662–668.PubMedCrossRefGoogle Scholar
  14. 14.
    Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assay. J. Immunol. Methods 1983; 65: 55–63.PubMedCrossRefGoogle Scholar
  15. 15.
    Pujol-Borrel R, Todd I, Mala Doshi, Gray D, Feldmann M, Bottazzo GF. Differential expression and regulation of MHC products in the endocrine and exocrine cells of the human pancreas. Clin. Exp. Immunol. 1986; 65: 128–139.Google Scholar
  16. 16.
    Houghton AN, Thomson TM, Gross D, Oettgen H, Old LJ. Surface antigens on melanoma and melanocytes. Specificity of induction of la antigens by human γ-interferon. J. Exp. Med. 1984; 160: 255–269.PubMedCrossRefGoogle Scholar
  17. 17.
    Le J, Yip YK, Vilcek J. Cytolytic activity of interferon-gamma and its synergism with 5-fluorouracil. Int. J. Cancer 1984; 34: 495–500.PubMedCrossRefGoogle Scholar
  18. 18.
    Aggarwal BB, Eessalu TE. Induction of receptors for tumor necrosis factor-α by interferons is not a major mechanism for their synergistic cytotoxic response. J. Biol. Chem. 1987; 262: 10,000–10,007.Google Scholar
  19. 19.
    Ruggiero V, Tavernier J, Fiers W, Baglioni C. Induction of the synthesis of tumor necrosis factor receptors by interferon-γ. J. Immunol. 1986; 136: 2445–2450.PubMedGoogle Scholar
  20. 20.
    Takikawa O, Kuroiwa T, Yamazaki F, Kido R. Mechanism of Interferon-action: characterization of indoleamine 2,3-dioxygenase in cultured human cells induced by interferon-7 and evaluation of the enzyme-mediated typtophan degradation in its anticellular activity. J. Biol. Chem. 1988; 263; 2041–2048.PubMedGoogle Scholar
  21. 21.
    Ozaki Y, Edelstein MP, Duch DS. Induction of indoleamine 2,3-dioxygenase: a mechanism of the antitumor activity of interferon-γ. Proc. Natl. Acad. Sci. USA 1988; 85: 1242–1246.PubMedCrossRefGoogle Scholar
  22. 22.
    Fiers W, Beyaert R, Brouckaert P, Everaert B, Suffys P, Tavernier J, Van Haesebroeck B, Van Roy R. Tumor necrosis factor: a potential antitumor agent? J. of Interferon Res. 1987; 7: 627–634.Google Scholar
  23. 23.
    Wong GHW, Goeddel DB. Induction of manganese Superoxide dismutase by tumor necrosis factor: possible protective mechanism. Science (Washington, DC) 1988; 242: 941–944.CrossRefGoogle Scholar
  24. 24.
    Raitano AB, Korc M, Scuderi P. Alterations in cytokine binding induced by tumor necrosis factor alpha and gamma interferon on human pancreatic carcinoma cells. J. Cellular Biochem. 1988; Suppl. 12A: 208.Google Scholar
  25. 25.
    Ucer U, Bartsch H, Scheurich P, Pfizenmaier K. Biological effects of interferon on human tumor cells: quantity and affinity of cell membrane receptors for 7IFN in relation to growth inhibition and induction of HLA-DR expression. Int. J. Cancer 1985; 41:0 103–108.CrossRefGoogle Scholar
  26. 26.
    Pfizenmaier K, Bartsch H, Scheurich P, Seliger B, Ucer U, Vehmeyer K, Nagel, GA. Differential γ-interferon response of human colon carcinoma cells: inhibition of proliferation and modulation of immunogenicity as independent effects of interferon on tumor cell growth. Cancer Res. 1985; 45: 3503–3509.PubMedGoogle Scholar

Copyright information

© Humana Press Inc. 1990

Authors and Affiliations

  • Arthur B. Raitano
    • 1
    • 2
  • Philip Scuderi
    • 1
    • 2
  • Murray Korc
    • 1
    • 2
  1. 1.Departments of Microbiology and Immunology, Internal Medicine, Biochemistry, and the Arizona Cancer CenterUniversity of Arizona School of MedicineTuscon
  2. 2.Section of Endocrinology, Room 6411Arizona Health Sciences CenterTuscon

Personalised recommendations